Kimura et al., 2008 - Google Patents
Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosisKimura et al., 2008
View HTML- Document ID
- 12083450774259767399
- Author
- Kimura K
- Iwano M
- Higgins D
- Yamaguchi Y
- Nakatani K
- Harada K
- Kubo A
- Akai Y
- Rankin E
- Neilson E
- Haase V
- Saito Y
- Publication year
- Publication venue
- American Journal of Physiology-Renal Physiology
External Links
Snippet
Chronic hypoxia accelerates renal fibrosis. The chief mediator of the hypoxic response is hypoxia-inducible factor 1 (HIF-1) and its oxygen-sensitive component HIF-1α. HIF-1 regulates a wide variety of genes, some of which are closely associated with tissue fibrosis …
- 102100003042 HIF1A 0 title abstract description 78
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kimura et al. | Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis | |
| Gifford et al. | Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities | |
| Baumann et al. | Hypoxia-inducible factor-1α promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3 | |
| Kapitsinou et al. | Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury | |
| Haase | Hypoxia-inducible factors in the kidney | |
| Matoba et al. | Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α | |
| Higgins et al. | Hypoxic induction of Ctgf is directly mediated by Hif-1 | |
| Ding et al. | Sonic hedgehog signaling mediates epithelial–mesenchymal communication and promotes renal fibrosis | |
| Qi et al. | Integrated actions of transforming growth factor-β1 and connective tissue growth factor in renal fibrosis | |
| Wang et al. | Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesis | |
| Kapitsinou et al. | Molecular mechanisms of ischemic preconditioning in the kidney | |
| Kobayashi et al. | Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury | |
| Schley et al. | Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury | |
| Yang et al. | Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy | |
| Henderson Jr et al. | Inhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis | |
| Carnesecchi et al. | A key role for NOX4 in epithelial cell death during development of lung fibrosis | |
| Tharaux et al. | Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway | |
| Shoji et al. | Role of hypoxia in progressive chronic kidney disease and implications for therapy | |
| Macconi et al. | MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition | |
| Boffa et al. | Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism | |
| Liu et al. | Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NF. κB-dependent mechanisms in mice | |
| Zhou et al. | Mutual antagonism of Wilms’ tumor 1 and β-catenin dictates podocyte health and disease | |
| Hassane et al. | Elevated TGFβ–Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease | |
| Michailidou et al. | Adipocyte pseudohypoxia suppresses lipolysis and facilitates benign adipose tissue expansion | |
| Gerl et al. | Inducible glomerular erythropoietin production in the adult kidney |